Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Merck Canada Inc.

Linda Brockunier

Emma R Parmee

Jian Guo

Subharekha Raghavan

Rui Liang

Karen M Marcantonio

Ann E Weber

Dong Xiao

Yusheng Xiong

Anthony K Ogawa

Wanying Sun

Weiguo Liu

John E Stelmach

Keith Rosauer

Ravi P Nargund

Anandan Palani

Amjad Ali

Peng Li

Sung-Sau So

Scott D Edmondson

Xing Dai

Shuwen He

Fa-Xiang Ding

Hong Liu

Zhuyan Guo

Helen Y Chen

Santhosh Francis Neelamkavil

Yan Guo

Eric Mertz

Darby Schmidt

Shouwu Miao

Christopher W Plummer

Xuanjia Peng

Nicolas Zorn

Jonathan A Groeper

Tesfaye Biftu

Samuel Chackalamannil

William K Hagmann

Yongxin Han

Duane A Burnett

Hubert B Josien

Qun Dang

Xianhai Huang

Tao Guo

Barbara A Pio

Michael W Miller

Hong Shen

Srikanth Venkatraman

Jinlong Jiang

Yan Xia

Sherman Tim Waddell

Dooseop Kim

Haifeng Tang

Duane E DeMong

James R Tata

Patrick A Pinto

Ying-Duo Gao

Alan W Hruza

Rongze Kuang

Harry R Chobanian

Mariappan Chelliah

Cameron James Smith

Xibin Liao

Yi-Heng Chen

Francisco Velazquez

Unmesh G Shah

Jiang Chang

Joseph Leslie Duffy

Weidong Pan

Min K Park

Heping Wu

Martin C Clasby

Dann LeRoy Parker, Jr

Hong Li

Thomas A Bara

Sathesh P Bhat

Austin Chen

Zhong Lai

Yi Zang

Alejandro Crespo

Alan Whitehead

Joie Garfunkle

Hongwu Wang

Ming Wang

Remond Moningka

Rudrajit Mal

Dipshikha Biswas

Olga Ornoski

Murali Rajagopalan

Xiaoqing Han

Charles Jayne

Teresa Beeson

George Scott Tria

Vince J Colandrea

Matthew J H Clements

Min Park

The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A, Q, A, M, W, Rand Rare as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

Factor XIa inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic bicyclic compounds

The present invention provides a compound of Formula I (The chemical formula should be inserted here.) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

Factor Xla inhibitors

The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. 

Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C

A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof. 

Soluble guanylate cyclase activators

The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver. 

The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds.

HCV NS3 protease inhibitors

Compounds of Formula I are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the Formula I. 

Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Pyrazole derivatives, compositions containing such compounds and methods of use

Pyrazole amides are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Pyrazole amide derivatives, compositions containing such compounds and methods of use

The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment. The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus.

Substituted pyrazoles, compositions containing such compounds and methods of use

Growing community of inventors

Orange, NJ, United States of America

Linda Brockunier